BR112015028501A2 - derivados de bipirazol como inibidores de jak - Google Patents
derivados de bipirazol como inibidores de jakInfo
- Publication number
- BR112015028501A2 BR112015028501A2 BR112015028501A BR112015028501A BR112015028501A2 BR 112015028501 A2 BR112015028501 A2 BR 112015028501A2 BR 112015028501 A BR112015028501 A BR 112015028501A BR 112015028501 A BR112015028501 A BR 112015028501A BR 112015028501 A2 BR112015028501 A2 BR 112015028501A2
- Authority
- BR
- Brazil
- Prior art keywords
- jak
- activity
- bipirazole
- derivatives
- diseases
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Abstract
abstract the present invention provides compounds of formula i: i or pharmaceutically acceptable salts thereof, as well as their compositions and methods of use, that inhibit the activity of janus kinase (jak) and are useful in the treatment of diseases related to the activity of jak including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases. tradução do resumo resumo "derivados de bipirazol como inibidores de jak" a presente invenção fornece compostos de fórmula i: i ou os seus sais aceitáveis, bem como as suas composições e métodos de utilização, que inibem a atividade da quinase janus (jak) e são úteis no tratamento de doenças relacionadas com a atividade de jak, incluindo, por exemplo, distúrbios inflamatórios, distúrbios farmaceuticamente autoimunes, câncer, e outras doenças.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361824683P | 2013-05-17 | 2013-05-17 | |
US61/824,683 | 2013-05-17 | ||
PCT/US2014/038388 WO2014186706A1 (en) | 2013-05-17 | 2014-05-16 | Bipyrazole derivatives as jak inhibitors |
Publications (3)
Publication Number | Publication Date |
---|---|
BR112015028501A2 true BR112015028501A2 (pt) | 2017-07-25 |
BR112015028501B1 BR112015028501B1 (pt) | 2022-11-01 |
BR112015028501B8 BR112015028501B8 (pt) | 2023-01-24 |
Family
ID=50983151
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112015028501A BR112015028501B8 (pt) | 2013-05-17 | 2014-05-16 | Compostos derivados de bipirazol, seus sais, composição compreendendo o composto ou o sal, método de inibição in vitro de uma atividade de jak1, e processo de preparação de sal de ácido fosfórico |
Country Status (35)
Country | Link |
---|---|
US (6) | US9382231B2 (pt) |
EP (5) | EP4275756A3 (pt) |
JP (4) | JP6415543B2 (pt) |
KR (3) | KR102341908B1 (pt) |
CN (2) | CN107698569B (pt) |
AR (2) | AR096330A1 (pt) |
AU (5) | AU2014265279B2 (pt) |
BR (1) | BR112015028501B8 (pt) |
CA (1) | CA2911536C (pt) |
CL (1) | CL2015003355A1 (pt) |
CR (2) | CR20190156A (pt) |
CY (3) | CY1119105T1 (pt) |
DK (3) | DK3231801T3 (pt) |
EA (2) | EA039660B1 (pt) |
ES (4) | ES2626793T3 (pt) |
FI (1) | FI3786162T3 (pt) |
HK (2) | HK1221466A1 (pt) |
HR (4) | HRP20231048T1 (pt) |
HU (4) | HUE063817T2 (pt) |
IL (4) | IL242453B (pt) |
LT (4) | LT2997023T (pt) |
ME (2) | ME03355B (pt) |
MX (2) | MX2020004506A (pt) |
MY (1) | MY174788A (pt) |
PE (2) | PE20160126A1 (pt) |
PH (2) | PH12015502563A1 (pt) |
PL (3) | PL2997023T3 (pt) |
PT (4) | PT3786162T (pt) |
RS (4) | RS61482B1 (pt) |
SG (2) | SG11201509180WA (pt) |
SI (4) | SI3527263T1 (pt) |
TR (1) | TR201905814T4 (pt) |
TW (3) | TW202116320A (pt) |
UA (1) | UA117830C2 (pt) |
WO (1) | WO2014186706A1 (pt) |
Families Citing this family (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101391900B1 (ko) | 2005-12-13 | 2014-05-02 | 인사이트 코포레이션 | 야누스 키나아제 억제제로서의 헤테로아릴 치환된 피롤로[2,3-b]피리딘 및 피롤로[2,3-b]피리미딘 |
KR101549876B1 (ko) | 2007-06-13 | 2015-09-03 | 인사이트 코포레이션 | 야누스 키나제 억제제(R)―3―(4―(7H―피롤로[2,3-d]피리미딘―4―일)―1H―피라졸―1―일)―3―사이클로펜틸프로판니트릴의 염 |
ES2487542T3 (es) | 2009-05-22 | 2014-08-21 | Incyte Corporation | Derivados de N-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo[2,3-d]pirimidinas y pirrol-3-il-pirrolo[2,3-d]pirimidinas como inhibidores de cinasas Janus |
NZ596374A (en) | 2009-05-22 | 2014-01-31 | Incyte Corp | 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors |
BRPI1015135B1 (pt) | 2009-06-29 | 2021-08-03 | Incyte Holdings Corporation | Pirimidinonas inibidoras de pi3k, composição compreendendo tais compostos, bem como usos dos mesmos |
US9249145B2 (en) | 2009-09-01 | 2016-02-02 | Incyte Holdings Corporation | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
SI3050882T1 (en) | 2010-03-10 | 2018-06-29 | Incyte Holdings Corporation | Piperidin-4-yl azetidine derivatives, as inhibitors of JAK1 |
TWI499421B (zh) | 2010-05-21 | 2015-09-11 | Incyte Corp | Jak抑制劑的局部製劑 |
PE20140146A1 (es) | 2010-11-19 | 2014-02-06 | Incyte Corp | Derivados de pirrolopiridina y pirrolopirimidina sustituidos con ciclobutilo como inhibidores de jak |
JP5961187B2 (ja) | 2010-12-20 | 2016-08-02 | インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation | Pi3k阻害剤としてのn−(1−(置換フェニル)エチル)−9h−プリン−6−アミン |
ES2560611T3 (es) | 2011-06-20 | 2016-02-22 | Incyte Holdings Corporation | Derivados de fenil de azetidinilo, carboxamida de piridilo o pirazinilo como inhibidores de JAK |
TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為jak抑制劑之環己基氮雜環丁烷衍生物 |
WO2013033569A1 (en) | 2011-09-02 | 2013-03-07 | Incyte Corporation | Heterocyclylamines as pi3k inhibitors |
UA111854C2 (uk) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
AR090548A1 (es) | 2012-04-02 | 2014-11-19 | Incyte Corp | Azaheterociclobencilaminas biciclicas como inhibidores de pi3k |
TW201406761A (zh) | 2012-05-18 | 2014-02-16 | Incyte Corp | 做爲jak抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物 |
AR093308A1 (es) | 2012-11-01 | 2015-05-27 | Incyte Corp | Derivados triciclicos fusionados de tiofeno como inhibidores de jak |
UA120834C2 (uk) | 2012-11-15 | 2020-02-25 | Інсайт Холдінгс Корпорейшн | Лікарські форми руксолітинібу зі сповільненим вивільненням |
CA3091179C (en) | 2013-03-06 | 2023-01-17 | Incyte Holdings Corporation | Processes and intermediates for making a jak inhibitor |
UA117830C2 (uk) | 2013-05-17 | 2018-10-10 | Інсайт Корпорейшн | Похідні біпіразолу як інгібітори jak |
CN105579032A (zh) | 2013-08-07 | 2016-05-11 | 因赛特公司 | Jak1抑制剂的持续释放剂型 |
CN106456773A (zh) * | 2014-02-28 | 2017-02-22 | 因赛特公司 | 用于治疗骨髓增生异常综合征的jak1抑制剂 |
US10064866B2 (en) | 2014-04-08 | 2018-09-04 | Incyte Corporation | Treatment of B-cell malignancies by a combination JAK and PI3K inhibitors |
CA2947418A1 (en) | 2014-04-30 | 2015-11-05 | Incyte Corporation | Processes of preparing a jak1 inhibitor and new forms thereto |
US9498467B2 (en) | 2014-05-30 | 2016-11-22 | Incyte Corporation | Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1 |
US10077277B2 (en) | 2014-06-11 | 2018-09-18 | Incyte Corporation | Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors |
WO2016172712A2 (en) | 2015-04-23 | 2016-10-27 | Sydnexis, Inc. | Ophthalmic composition |
US9421199B2 (en) | 2014-06-24 | 2016-08-23 | Sydnexis, Inc. | Ophthalmic composition |
US11382909B2 (en) | 2014-09-05 | 2022-07-12 | Sydnexis, Inc. | Ophthalmic composition |
US9586949B2 (en) | 2015-02-09 | 2017-03-07 | Incyte Corporation | Aza-heteroaryl compounds as PI3K-gamma inhibitors |
CR20170389A (es) | 2015-02-27 | 2018-01-26 | Incyte Corp | Sales de inhibidor de p13k y procesos de preparación |
US9732097B2 (en) | 2015-05-11 | 2017-08-15 | Incyte Corporation | Process for the synthesis of a phosphoinositide 3-kinase inhibitor |
US9988401B2 (en) | 2015-05-11 | 2018-06-05 | Incyte Corporation | Crystalline forms of a PI3K inhibitor |
EP3302426A4 (en) * | 2015-05-29 | 2018-12-05 | Sydnexis, Inc. | D2o stabilized pharmaceutical formulations |
WO2017079519A1 (en) | 2015-11-06 | 2017-05-11 | Incyte Corporation | Heterocyclic compounds as pi3k-gamma inhibitors |
TW201734003A (zh) | 2016-01-05 | 2017-10-01 | 英塞特公司 | 作為PI3K-γ抑制劑之吡啶及嘧啶化合物 |
AR108875A1 (es) | 2016-06-24 | 2018-10-03 | Incyte Corp | COMPUESTOS HETEROCÍCLICOS COMO INHIBIDORES DE PI3K-g |
CN107759623B (zh) * | 2016-08-23 | 2020-08-14 | 苏州旺山旺水生物医药有限公司 | Jak抑制剂的中间体及其制备方法 |
BR112019004486A2 (pt) * | 2016-09-06 | 2019-05-28 | Hoffmann La Roche | compostos de 8-(azetidin-1-il)-[1,2,4] triazolo [1,5a] piridinil, composições e métodos de uso dos mesmos |
CR20200214A (es) | 2017-10-18 | 2020-07-25 | Incyte Corp | ALCOHOLES TERCIARIOS COMO INHIBIDORES DE PI3K-y |
WO2019113487A1 (en) | 2017-12-08 | 2019-06-13 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
MA51771B1 (fr) | 2018-01-30 | 2022-03-31 | Incyte Corp | Procédés de préparation de (1-(3-fluoro-2-(trifluorométhyl)isonicotinyl)pipéridine-4-one) |
US11103510B2 (en) | 2018-02-16 | 2021-08-31 | Incyte Corporation | JAK1 pathway inhibitors for the treatment of cytokine-related disorders |
EP3775284A1 (en) | 2018-03-30 | 2021-02-17 | Incyte Corporation | Biomarkers for inflammatory skin disease |
SG11202009441PA (en) * | 2018-03-30 | 2020-10-29 | Incyte Corp | Treatment of hidradenitis suppurativa using jak inhibitors |
WO2019200030A1 (en) * | 2018-04-13 | 2019-10-17 | Incyte Corporation | Biomarkers for graft-versus-host disease |
CN108484468A (zh) * | 2018-05-11 | 2018-09-04 | 南京大学 | 芳基氮杂环丁烷类化合物的制备方法 |
DK3847175T3 (da) | 2018-09-05 | 2024-03-18 | Incyte Corp | Krystallinske former af en phosphoinositid-3-kinase- (pi3k) inhibitor |
SG11202104321PA (en) | 2018-10-31 | 2021-05-28 | Incyte Corp | Combination therapy for treatment of hematological diseases |
CN113692278A (zh) | 2018-12-19 | 2021-11-23 | 因赛特公司 | 用于治疗胃肠道疾病的jak1途径抑制剂 |
MX2021010545A (es) | 2019-03-05 | 2021-11-17 | Incyte Corp | Inhibidores de la vía de cinasa janus 1 (jak1) para el tratamiento de la disfunción crónica del aloinjerto pulmonar. |
WO2020191041A2 (en) | 2019-03-19 | 2020-09-24 | Incyte Corporation | Biomarkers for vitiligo |
JP2022526713A (ja) | 2019-03-21 | 2022-05-26 | オンクセオ | がんの処置のための、キナーゼ阻害剤と組み合わせたDbait分子 |
CA3157499A1 (en) | 2019-10-10 | 2021-04-15 | Incyte Corporation | Biomarkers for graft-versus-host disease |
WO2021072098A1 (en) | 2019-10-10 | 2021-04-15 | Incyte Corporation | Biomarkers for graft-versus-host disease |
WO2021076124A1 (en) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Use of jak1 inhibitors for the treatment of cutaneous lupus erythematosus and lichen planus (lp) |
CN114761006A (zh) | 2019-11-08 | 2022-07-15 | Inserm(法国国家健康医学研究院) | 对激酶抑制剂产生耐药性的癌症的治疗方法 |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
KR20230027086A (ko) | 2020-06-02 | 2023-02-27 | 인사이트 코포레이션 | Jak1 저해제의 제조 공정 |
US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
JP2023539126A (ja) | 2020-08-18 | 2023-09-13 | インサイト・コーポレイション | Jak阻害剤を調製するための方法及び中間体 |
EP4200278A1 (en) | 2020-08-18 | 2023-06-28 | Incyte Corporation | Process and intermediates for preparing a jak1 inhibitor |
CN112159394B (zh) * | 2020-10-09 | 2021-10-22 | 嘉兴特科罗生物科技有限公司 | 一种作为jak激酶抑制剂的小分子化合物及其用途 |
US20220202834A1 (en) | 2020-12-04 | 2022-06-30 | Incyte Corporation | Jak inhibitor with a vitamin d analog for treatment of skin diseases |
KR20230118118A (ko) | 2020-12-08 | 2023-08-10 | 인사이트 코포레이션 | 백반증의 치료를 위한 jak1 경로 저해제 |
CN114081889A (zh) * | 2020-12-29 | 2022-02-25 | 上海岸阔医药科技有限公司 | 预防或治疗egfr功能异常相关的副作用的方法 |
TW202237083A (zh) | 2021-01-11 | 2022-10-01 | 美商英塞特公司 | 包含jak路徑抑制劑及rock抑制劑之組合療法 |
CA3219092A1 (en) | 2021-05-03 | 2022-11-10 | Incyte Corporation | Jak1 pathway inhibitors for the treatment of prurigo nodularis |
WO2024030600A1 (en) | 2022-08-05 | 2024-02-08 | Incyte Corporation | Treatment of urticaria using jak inhibitors |
CN117186078A (zh) * | 2023-11-06 | 2023-12-08 | 药康众拓(北京)医药科技有限公司 | 氘代氮杂环丁烷类jak抑制剂药物及用途 |
Family Cites Families (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5646749A (en) * | 1979-09-26 | 1981-04-28 | Mitsui Toatsu Chemicals | Protective sheet for surface |
JPS60106847U (ja) | 1983-12-27 | 1985-07-20 | 富士重工業株式会社 | 室外後写鏡 |
JP2650681B2 (ja) | 1987-07-10 | 1997-09-03 | 株式会社ブリヂストン | 空気ばね |
US5521184A (en) | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
CN1152031C (zh) | 1998-08-11 | 2004-06-02 | 诺瓦提斯公司 | 具有血管生成抑制活性的异喹啉衍生物 |
US6133031A (en) | 1999-08-19 | 2000-10-17 | Isis Pharmaceuticals Inc. | Antisense inhibition of focal adhesion kinase expression |
GB9905075D0 (en) | 1999-03-06 | 1999-04-28 | Zeneca Ltd | Chemical compounds |
GB0004890D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
KR100786927B1 (ko) | 2000-06-28 | 2007-12-17 | 스미스클라인비이참피이엘시이 | 습식 분쇄방법 |
JP4456365B2 (ja) | 2001-09-19 | 2010-04-28 | アベンティス・ファーマ・ソシエテ・アノニム | 化合物 |
ATE335490T1 (de) | 2001-10-30 | 2006-09-15 | Novartis Pharma Gmbh | Staurosporin-derivate als hemmer der flt3- rezeptor-tyrosinkinase-wirkung |
TW200406374A (en) | 2002-05-29 | 2004-05-01 | Novartis Ag | Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases |
GB0215676D0 (en) | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
TWI335913B (en) | 2002-11-15 | 2011-01-11 | Vertex Pharma | Diaminotriazoles useful as inhibitors of protein kinases |
UA80767C2 (en) | 2002-12-20 | 2007-10-25 | Pfizer Prod Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
GB0305929D0 (en) | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
PE20050952A1 (es) | 2003-09-24 | 2005-12-19 | Novartis Ag | Derivados de isoquinolina como inhibidores de b-raf |
WO2006056399A2 (en) | 2004-11-24 | 2006-06-01 | Novartis Ag | Combinations of jak inhibitors and at least one of bcr-abl, flt-3, fak or raf kinase inhibitors |
KR101391900B1 (ko) | 2005-12-13 | 2014-05-02 | 인사이트 코포레이션 | 야누스 키나아제 억제제로서의 헤테로아릴 치환된 피롤로[2,3-b]피리딘 및 피롤로[2,3-b]피리미딘 |
CL2008001709A1 (es) | 2007-06-13 | 2008-11-03 | Incyte Corp | Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras. |
KR101549876B1 (ko) | 2007-06-13 | 2015-09-03 | 인사이트 코포레이션 | 야누스 키나제 억제제(R)―3―(4―(7H―피롤로[2,3-d]피리미딘―4―일)―1H―피라졸―1―일)―3―사이클로펜틸프로판니트릴의 염 |
BRPI0820544A2 (pt) * | 2007-11-16 | 2015-06-16 | Incyte Corp | 4-pirazolil-n-arilpirimidin-2-aminas e pirazolil-n-heteroarilpirimidin-2-aminas como inibidores de janus cinase |
EP2288610B8 (en) * | 2008-03-11 | 2016-10-12 | Incyte Holdings Corporation | Azetidine and cyclobutane derivatives as jak inhibitors |
CL2009001884A1 (es) | 2008-10-02 | 2010-05-14 | Incyte Holdings Corp | Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco. |
JOP20190231A1 (ar) | 2009-01-15 | 2017-06-16 | Incyte Corp | طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به |
NZ596374A (en) | 2009-05-22 | 2014-01-31 | Incyte Corp | 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors |
ES2487542T3 (es) | 2009-05-22 | 2014-08-21 | Incyte Corporation | Derivados de N-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo[2,3-d]pirimidinas y pirrol-3-il-pirrolo[2,3-d]pirimidinas como inhibidores de cinasas Janus |
US9249145B2 (en) | 2009-09-01 | 2016-02-02 | Incyte Holdings Corporation | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
CN102596960B (zh) | 2009-10-09 | 2016-01-20 | 因西特控股公司 | 3-(4-(7H-吡咯并[2,3-d]嘧啶-4-基)-1H-吡唑-1-基)-3-环戊基丙腈的羟基衍生物、酮基衍生物和葡糖苷酸衍生物 |
CA2790070C (en) | 2010-02-18 | 2018-03-06 | Incyte Corporation | Cyclobutane and methylcyclobutane derivatives as janus kinase inhibitors |
SI3050882T1 (en) | 2010-03-10 | 2018-06-29 | Incyte Holdings Corporation | Piperidin-4-yl azetidine derivatives, as inhibitors of JAK1 |
CN102985424B (zh) * | 2010-04-14 | 2015-03-11 | 阵列生物制药公司 | 5,7-取代的-咪唑并[1,2-c]嘧啶 |
TWI499421B (zh) | 2010-05-21 | 2015-09-11 | Incyte Corp | Jak抑制劑的局部製劑 |
JP5917544B2 (ja) | 2010-11-19 | 2016-05-18 | インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation | Jak阻害剤としての複素環置換ピロロピリジンおよびピロロピリミジン |
PE20140146A1 (es) | 2010-11-19 | 2014-02-06 | Incyte Corp | Derivados de pirrolopiridina y pirrolopirimidina sustituidos con ciclobutilo como inhibidores de jak |
CA2820109C (en) | 2010-12-10 | 2018-01-09 | Rottapharm S.P.A. | Pyridine amide derivatives as ep4 receptor antagonists |
SG192910A1 (en) | 2011-02-24 | 2013-09-30 | Massachusetts Inst Technology | ALTERNATIVELY SPLICED mRNA ISOFORMS AS PROGNOSTIC INDICATORS FOR METASTATIC CANCER |
ES2560611T3 (es) | 2011-06-20 | 2016-02-22 | Incyte Holdings Corporation | Derivados de fenil de azetidinilo, carboxamida de piridilo o pirazinilo como inhibidores de JAK |
TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為jak抑制劑之環己基氮雜環丁烷衍生物 |
UA111854C2 (uk) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
WO2013043962A1 (en) | 2011-09-22 | 2013-03-28 | Merck Sharp & Dohme Corp. | Cyanomethylpyrazole carboxamides as janus kinase inhibitors |
TW201406761A (zh) * | 2012-05-18 | 2014-02-16 | Incyte Corp | 做爲jak抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物 |
AR093308A1 (es) | 2012-11-01 | 2015-05-27 | Incyte Corp | Derivados triciclicos fusionados de tiofeno como inhibidores de jak |
UA120834C2 (uk) | 2012-11-15 | 2020-02-25 | Інсайт Холдінгс Корпорейшн | Лікарські форми руксолітинібу зі сповільненим вивільненням |
CA3091179C (en) | 2013-03-06 | 2023-01-17 | Incyte Holdings Corporation | Processes and intermediates for making a jak inhibitor |
JO3603B1 (ar) | 2013-05-17 | 2020-07-05 | Janssen Sciences Ireland Uc | مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي |
EP2803668A1 (en) | 2013-05-17 | 2014-11-19 | Boehringer Ingelheim International Gmbh | Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles |
UA117830C2 (uk) | 2013-05-17 | 2018-10-10 | Інсайт Корпорейшн | Похідні біпіразолу як інгібітори jak |
US9371282B2 (en) | 2013-05-17 | 2016-06-21 | Centrexion Therapeutics Corporation | Somatostatin receptor subtype 4 (SSTR4) agonists |
TW201512193A (zh) | 2013-05-17 | 2015-04-01 | Hoffmann La Roche | 用於治療及防治b型肝炎病毒感染之新穎6-橋聯雜芳基二氫嘧啶 |
CN105579032A (zh) | 2013-08-07 | 2016-05-11 | 因赛特公司 | Jak1抑制剂的持续释放剂型 |
CN106456773A (zh) | 2014-02-28 | 2017-02-22 | 因赛特公司 | 用于治疗骨髓增生异常综合征的jak1抑制剂 |
CA2947418A1 (en) | 2014-04-30 | 2015-11-05 | Incyte Corporation | Processes of preparing a jak1 inhibitor and new forms thereto |
US9498467B2 (en) | 2014-05-30 | 2016-11-22 | Incyte Corporation | Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1 |
US9549916B2 (en) | 2014-12-16 | 2017-01-24 | Novartis Ag | Isoxazole hydroxamic acid compounds as LpxC inhibitors |
KR20230027086A (ko) | 2020-06-02 | 2023-02-27 | 인사이트 코포레이션 | Jak1 저해제의 제조 공정 |
US20220202834A1 (en) | 2020-12-04 | 2022-06-30 | Incyte Corporation | Jak inhibitor with a vitamin d analog for treatment of skin diseases |
-
2014
- 2014-05-16 UA UAA201512465A patent/UA117830C2/uk unknown
- 2014-05-16 AR ARP140101971A patent/AR096330A1/es active IP Right Grant
- 2014-05-16 KR KR1020157035750A patent/KR102341908B1/ko active IP Right Grant
- 2014-05-16 TR TR2019/05814T patent/TR201905814T4/tr unknown
- 2014-05-16 LT LTEP14732705.0T patent/LT2997023T/lt unknown
- 2014-05-16 ME MEP-2019-79A patent/ME03355B/me unknown
- 2014-05-16 ES ES14732705.0T patent/ES2626793T3/es active Active
- 2014-05-16 RS RS20210074A patent/RS61482B1/sr unknown
- 2014-05-16 PT PT202015939T patent/PT3786162T/pt unknown
- 2014-05-16 LT LTEP17158350.3T patent/LT3231801T/lt unknown
- 2014-05-16 HU HUE20201593A patent/HUE063817T2/hu unknown
- 2014-05-16 TW TW110101630A patent/TW202116320A/zh unknown
- 2014-05-16 PE PE2015002406A patent/PE20160126A1/es unknown
- 2014-05-16 DK DK17158350.3T patent/DK3231801T3/en active
- 2014-05-16 FI FIEP20201593.9T patent/FI3786162T3/fi active
- 2014-05-16 SG SG11201509180WA patent/SG11201509180WA/en unknown
- 2014-05-16 US US14/279,929 patent/US9382231B2/en active Active
- 2014-05-16 SI SI201431754T patent/SI3527263T1/sl unknown
- 2014-05-16 EP EP23185889.5A patent/EP4275756A3/en active Pending
- 2014-05-16 EA EA202090291A patent/EA039660B1/ru unknown
- 2014-05-16 PT PT17158350T patent/PT3231801T/pt unknown
- 2014-05-16 EP EP18215671.1A patent/EP3527263B1/en active Active
- 2014-05-16 HU HUE14732705A patent/HUE033587T2/hu unknown
- 2014-05-16 CN CN201711000293.3A patent/CN107698569B/zh active Active
- 2014-05-16 CR CR20190156A patent/CR20190156A/es unknown
- 2014-05-16 PL PL14732705T patent/PL2997023T3/pl unknown
- 2014-05-16 DK DK18215671.1T patent/DK3527263T3/da active
- 2014-05-16 HR HRP20231048TT patent/HRP20231048T1/hr unknown
- 2014-05-16 DK DK20201593.9T patent/DK3786162T3/da active
- 2014-05-16 EP EP17158350.3A patent/EP3231801B1/en active Active
- 2014-05-16 MX MX2020004506A patent/MX2020004506A/es unknown
- 2014-05-16 MX MX2015015738A patent/MX2015015738A/es active IP Right Grant
- 2014-05-16 KR KR1020227030853A patent/KR20220127371A/ko active IP Right Grant
- 2014-05-16 LT LTEP18215671.1T patent/LT3527263T/lt unknown
- 2014-05-16 RS RS20190315A patent/RS58743B1/sr unknown
- 2014-05-16 ME MEP-2017-116A patent/ME02763B/me unknown
- 2014-05-16 TW TW103117400A patent/TWI664176B/zh active
- 2014-05-16 TW TW108103947A patent/TWI719401B/zh active
- 2014-05-16 PL PL18215671T patent/PL3527263T3/pl unknown
- 2014-05-16 EA EA201592199A patent/EA036448B1/ru unknown
- 2014-05-16 KR KR1020217030190A patent/KR102442747B1/ko active IP Right Grant
- 2014-05-16 SI SI201431118T patent/SI3231801T1/sl unknown
- 2014-05-16 EP EP20201593.9A patent/EP3786162B1/en active Active
- 2014-05-16 WO PCT/US2014/038388 patent/WO2014186706A1/en active Application Filing
- 2014-05-16 JP JP2016514126A patent/JP6415543B2/ja active Active
- 2014-05-16 BR BR112015028501A patent/BR112015028501B8/pt active IP Right Grant
- 2014-05-16 SI SI201430239A patent/SI2997023T1/sl unknown
- 2014-05-16 HU HUE17158350A patent/HUE043573T2/hu unknown
- 2014-05-16 PT PT147327050T patent/PT2997023T/pt unknown
- 2014-05-16 ES ES18215671T patent/ES2845210T3/es active Active
- 2014-05-16 EP EP14732705.0A patent/EP2997023B9/en active Active
- 2014-05-16 SG SG10201709469SA patent/SG10201709469SA/en unknown
- 2014-05-16 ES ES20201593T patent/ES2960731T3/es active Active
- 2014-05-16 PL PL17158350T patent/PL3231801T3/pl unknown
- 2014-05-16 LT LTEP20201593.9T patent/LT3786162T/lt unknown
- 2014-05-16 MY MYPI2015002767A patent/MY174788A/en unknown
- 2014-05-16 ES ES17158350T patent/ES2720073T3/es active Active
- 2014-05-16 HU HUE18215671A patent/HUE053122T2/hu unknown
- 2014-05-16 RS RS20230782A patent/RS64591B1/sr unknown
- 2014-05-16 CN CN201480032106.8A patent/CN105452239B/zh active Active
- 2014-05-16 PE PE2020000001A patent/PE20200527A1/es unknown
- 2014-05-16 CA CA2911536A patent/CA2911536C/en active Active
- 2014-05-16 RS RS20170526A patent/RS56012B1/sr unknown
- 2014-05-16 PT PT182156711T patent/PT3527263T/pt unknown
- 2014-05-16 AU AU2014265279A patent/AU2014265279B2/en active Active
- 2014-05-16 SI SI201432046T patent/SI3786162T1/sl unknown
-
2015
- 2015-11-04 IL IL24245315A patent/IL242453B/en active IP Right Grant
- 2015-11-12 PH PH12015502563A patent/PH12015502563A1/en unknown
- 2015-11-13 CL CL2015003355A patent/CL2015003355A1/es unknown
- 2015-12-03 CR CR20150633A patent/CR20150633A/es unknown
-
2016
- 2016-06-20 US US15/187,296 patent/US9926301B2/en active Active
- 2016-08-11 HK HK16109588.1A patent/HK1221466A1/zh unknown
-
2017
- 2017-05-29 HR HRP20170795TT patent/HRP20170795T1/hr unknown
- 2017-06-08 CY CY20171100610T patent/CY1119105T1/el unknown
-
2018
- 2018-02-15 US US15/897,598 patent/US10435392B2/en active Active
- 2018-04-18 HK HK18105021.2A patent/HK1245769B/zh unknown
- 2018-08-31 AU AU2018223058A patent/AU2018223058B2/en active Active
- 2018-10-02 PH PH12018502125A patent/PH12018502125A1/en unknown
- 2018-10-02 JP JP2018187613A patent/JP6775560B2/ja active Active
-
2019
- 2019-01-22 IL IL264409A patent/IL264409B/en active IP Right Grant
- 2019-04-16 HR HRP20190713TT patent/HRP20190713T1/hr unknown
- 2019-05-10 CY CY20191100510T patent/CY1121763T1/el unknown
- 2019-08-29 US US16/555,620 patent/US11001571B2/en active Active
-
2020
- 2020-02-17 AR ARP200100433A patent/AR118120A2/es unknown
- 2020-03-19 AU AU2020202000A patent/AU2020202000B2/en active Active
- 2020-10-06 JP JP2020168950A patent/JP7126741B2/ja active Active
-
2021
- 2021-01-22 CY CY20211100050T patent/CY1123756T1/el unknown
- 2021-01-22 HR HRP20210119TT patent/HRP20210119T1/hr unknown
- 2021-04-13 US US17/229,397 patent/US11591318B2/en active Active
- 2021-04-26 IL IL282644A patent/IL282644B/en unknown
- 2021-04-29 AU AU2021202685A patent/AU2021202685B2/en active Active
- 2021-10-17 IL IL287313A patent/IL287313B/en unknown
-
2022
- 2022-08-10 JP JP2022128042A patent/JP2022163162A/ja active Pending
- 2022-10-31 AU AU2022263454A patent/AU2022263454B2/en active Active
-
2023
- 2023-01-24 US US18/101,014 patent/US11905275B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112015028501A2 (pt) | derivados de bipirazol como inibidores de jak | |
BR112015009942A2 (pt) | derivados de tiofeno fundidos tricíclicos como inibidores de jak | |
CY1120866T1 (el) | Παρεμποδιστες dna-pk | |
BR112015022643A2 (pt) | inibidores diidro-pirrolpiridinona | |
BR112012020693A2 (pt) | derivados de ciclobutano e metilciclobutano como inibidores de janus quinase | |
BR112015027951A8 (pt) | arilquinazolinas, seus usos, medicamento, composição farmacêutica, e kit | |
BR112015015635A2 (pt) | inibidores de quinases de proteínas | |
BR112015022861A2 (pt) | inibidores de bromodomínio | |
BR112013032720A2 (pt) | "derivados de azetidinil fenil, piridil ou pirazinil carboxamida como inibidores de jak, composição e uso dos referidos derivados" | |
MD4800B1 (ro) | Compuşi de aminopirimidinil ca inhibitori de JAK | |
BR112017011798A2 (pt) | 4,6-substituído-pirazolo[1,5-a] pirazinas como inibidores janus cinase | |
EA201591727A1 (ru) | Соединения биариламида в качестве ингибиторов киназы | |
BR112015022551A2 (pt) | inibidores de amido pirrol | |
BR112015021549A2 (pt) | inibidores de piridina cinase cdk9 | |
BR112017006073A2 (pt) | derivado de ácido 4-(4-(4-fenilureído-naftalen-1-il)óxi-piridin-2-il)amino-benzoico como inibidor de quinase de p38 | |
BR112015021701A2 (pt) | novos compostos inibidores da fosfoestearase tipo 10a | |
BR112015026023A2 (pt) | derivados de 2- aminopirido[4,3-d]pirimidin-5-ona e seu uso como inibidores de wee-1 | |
BR112015025354A2 (pt) | compostos di-hidropirido-pirimidínicos como inibidores de autotaxina | |
EA201590183A1 (ru) | Производные азаиндола, выступающие в качестве ингибиторов pi3k | |
DOP2015000214A (es) | Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a | |
BR112015023078A2 (pt) | inibidores de pirrolopirimindina cdk9 quinase | |
MX2017003016A (es) | Derivados de piridazinona como inhibidores de las fosfoinositido-3-cinasas. | |
BR112015025033A2 (pt) | prodrogas de inibidores da pde-5 do tipo pirimidina bicíclico substituídas | |
BR112015007507A2 (pt) | compostos de [3-heteroaril-2-trifluorometil-propil]-piperidin-1-ila ou –morfolin-4-ila como antagonistas trpa1 para o tratamento de doenças respiratórias | |
MY192305A (en) | Bipyrazole derivatives as jak inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 16/05/2014, OBSERVADAS AS CONDICOES LEGAIS |
|
B25A | Requested transfer of rights approved |
Owner name: INCYTE HOLDINGS CORPORATION (US) |